These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33527590)

  • 1. Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines.
    Yang Y; Ricketts CJ; Vocke CD; Killian JK; Padilla-Nash HM; Lang M; Wei D; Lee YH; Wangsa D; Sourbier C; Meltzer PS; Ried T; Merino MJ; Metwalli AR; Ball MW; Srinivasan R; Linehan WM
    Genes Chromosomes Cancer; 2021 Jun; 60(6):434-446. PubMed ID: 33527590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma.
    Pahwa R; Dubhashi J; Singh A; Jailwala P; Lobanov A; Thomas CJ; Ceribelli M; Wilson K; Ricketts CJ; Vocke CD; Wells C; Bottaro DP; Linehan WM; Neckers L; Srinivasan R
    J Exp Clin Cancer Res; 2022 Jun; 41(1):208. PubMed ID: 35754026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
    Pal SK; Ali SM; Yakirevich E; Geynisman DM; Karam JA; Elvin JA; Frampton GM; Huang X; Lin DI; Rosenzweig M; Lipson D; Stephens PJ; Ross JS; Miller VA; Agarwal N; Shuch B; Choueiri TK; Chung JH
    Eur Urol; 2018 Jan; 73(1):71-78. PubMed ID: 28592388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features.
    Denize T; Just PA; Sibony M; Blons H; Timsit MO; Drossart T; Jakubowicz D; Broudin C; Morini A; Molina T; Vano Y; Auvray-Kuentz M; Richard S; Mejean A; Gimenez Roqueplo AP; Burnichon N; Verkarre V
    Mod Pathol; 2021 Mar; 34(3):647-659. PubMed ID: 32770124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population.
    Lindor NM; Dechet CB; Greene MH; Jenkins RB; Zincke MT; Weaver AL; Wilson M; Zincke H; Liu W
    Genet Test; 2001; 5(2):101-6. PubMed ID: 11551094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.
    Schuller AG; Barry ER; Jones RD; Henry RE; Frigault MM; Beran G; Linsenmayer D; Hattersley M; Smith A; Wilson J; Cairo S; Déas O; Nicolle D; Adam A; Zinda M; Reimer C; Fawell SE; Clark EA; D'Cruz CM
    Clin Cancer Res; 2015 Jun; 21(12):2811-9. PubMed ID: 25779944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma.
    Bailey ST; Smith AM; Kardos J; Wobker SE; Wilson HL; Krishnan B; Saito R; Lee HJ; Zhang J; Eaton SC; Williams LA; Manocha U; Peters DJ; Pan X; Carroll TJ; Felsher DW; Walter V; Zhang Q; Parker JS; Yeh JJ; Moffitt RA; Leung JY; Kim WY
    Nat Commun; 2017 Jun; 8():15770. PubMed ID: 28593993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Papillary renal cell carcinoma: A review of the current therapeutic landscape.
    Courthod G; Tucci M; Di Maio M; Scagliotti GV
    Crit Rev Oncol Hematol; 2015 Oct; 96(1):100-12. PubMed ID: 26052049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array.
    Albiges L; Guegan J; Le Formal A; Verkarre V; Rioux-Leclercq N; Sibony M; Bernhard JC; Camparo P; Merabet Z; Molinie V; Allory Y; Orear C; Couvé S; Gad S; Patard JJ; Escudier B
    Clin Cancer Res; 2014 Jul; 20(13):3411-21. PubMed ID: 24658158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.
    Zhao H; Nolley R; Chan AMW; Rankin EB; Peehl DM
    Cancer Biol Ther; 2017 Nov; 18(11):863-871. PubMed ID: 27715452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dismantling papillary renal cell carcinoma classification: The heterogeneity of genetic profiles suggests several independent diseases.
    Marsaud A; Dadone B; Ambrosetti D; Baudoin C; Chamorey E; Rouleau E; Lefol C; Roussel JF; Fabas T; Cristofari G; Carpentier X; Michiels JF; Amiel J; Pedeutour F
    Genes Chromosomes Cancer; 2015 Jun; 54(6):369-82. PubMed ID: 25820192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal tubulocystic carcinoma is closely related to papillary renal cell carcinoma: implications for pathologic classification.
    Zhou M; Yang XJ; Lopez JI; Shah RB; Hes O; Shen SS; Li R; Yang Y; Lin F; Elson P; Sercia L; Magi-Galluzzi C; Tubbs R
    Am J Surg Pathol; 2009 Dec; 33(12):1840-9. PubMed ID: 19898225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clear cell and papillary renal cell carcinomas in hereditary papillary renal cell carcinoma (HPRCC) syndrome: a case report.
    Ferlicot S; Just PA; Compérat E; Rouleau E; Tissier F; Vaessen C; Richard S
    Diagn Pathol; 2021 Nov; 16(1):107. PubMed ID: 34801057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular characterization and therapeutic strategies of papillary renal cell carcinoma.
    Chen Q; Cheng L; Li Q
    Expert Rev Anticancer Ther; 2019 Feb; 19(2):169-175. PubMed ID: 30474436
    [No Abstract]   [Full Text] [Related]  

  • 15. Three-dimensional coculture provides an improved in vitro model for papillary renal cell carcinoma.
    Rosette KA; Lander SM; VanOpstall C; Looyenga BD
    Am J Physiol Renal Physiol; 2021 Jul; 321(1):F33-F46. PubMed ID: 34029144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Papillary renal cell carcinoma: a clinicopathological and whole-genome exon sequencing study.
    Liu K; Ren Y; Pang L; Qi Y; Jia W; Tao L; Hu Z; Zhao J; Zhang H; Li L; Yue H; Han J; Liang W; Hu J; Zou H; Yuan X; Li F
    Int J Clin Exp Pathol; 2015; 8(7):8311-35. PubMed ID: 26339402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
    Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
    Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.
    Choueiri TK; Plimack E; Arkenau HT; Jonasch E; Heng DYC; Powles T; Frigault MM; Clark EA; Handzel AA; Gardner H; Morgan S; Albiges L; Pal SK
    J Clin Oncol; 2017 Sep; 35(26):2993-3001. PubMed ID: 28644771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Papillary renal cell carcinoma with a somatic mutation in MET in a patient with autosomal dominant polycystic kidney disease.
    Zhang W; Tan AY; Blumenfeld J; Liu G; Michaeel A; Zhang T; Robinson BD; Salvatore SP; Kapur S; Donahue S; Bobb WO; Rennert H
    Cancer Genet; 2016; 209(1-2):11-20. PubMed ID: 26718059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic profiling of renal cell carcinoma in patients with end-stage renal disease.
    Inoue T; Matsuura K; Yoshimoto T; Nguyen LT; Tsukamoto Y; Nakada C; Hijiya N; Narimatsu T; Nomura T; Sato F; Nagashima Y; Kashima K; Hatakeyama S; Ohyama C; Numakura K; Habuchi T; Nakagawa M; Seto M; Mimata H; Moriyama M
    Cancer Sci; 2012 Mar; 103(3):569-76. PubMed ID: 22145865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.